Reversing chronic remodeling in heart failure

James Mudd, David A. Kass

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Chronic heart failure is a debilitating condition with significant morbidity, mortality and an increasing economic burden. The past 20 years have witnessed great strides in both medical and device-based therapies for heart failure. Central to these developments has been the ability to favorably reverse the chronic processes by which the failing heart remodels. In addition to pharmacotherapies, such as β-blockade, and inhibition of the renin-angiotensin-aldosterone system, surgical remodeling, containment devices and new methods to restore synchronous contraction have been added to the armamentarium, in some instances, providing clear improvement to both symptoms and mortality. In more advanced stages of heart failure, left ventricular-assist devices provide marked unloading of the failing ventricle and such therapy has provided unique insights into the molecular and cellular mechanisms underlying reverse remodeling, given the immediate access to cardiac tissue. Genetic and cellular approaches, as well as new small molecule targets, may provide future avenues for reverse remodeling of the failing heart, improving symptoms and disease outcome.

Original languageEnglish (US)
Pages (from-to)585-598
Number of pages14
JournalExpert Review of Cardiovascular Therapy
Volume5
Issue number3
DOIs
StatePublished - May 2007
Externally publishedYes

Fingerprint

Heart Failure
Equipment and Supplies
Heart-Assist Devices
Mortality
Renin-Angiotensin System
Economics
Morbidity
Drug Therapy
Therapeutics

Keywords

  • BH4
  • Cardiac function
  • Cardiac resynchronization therapy
  • Cardiac support device
  • Dyssynchrony
  • Heart failure
  • Left ventricular-assist device
  • PDE5a
  • Reverse remodelling

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Reversing chronic remodeling in heart failure. / Mudd, James; Kass, David A.

In: Expert Review of Cardiovascular Therapy, Vol. 5, No. 3, 05.2007, p. 585-598.

Research output: Contribution to journalArticle

@article{e4e4840a9df34b569ccc84057ea1518d,
title = "Reversing chronic remodeling in heart failure",
abstract = "Chronic heart failure is a debilitating condition with significant morbidity, mortality and an increasing economic burden. The past 20 years have witnessed great strides in both medical and device-based therapies for heart failure. Central to these developments has been the ability to favorably reverse the chronic processes by which the failing heart remodels. In addition to pharmacotherapies, such as β-blockade, and inhibition of the renin-angiotensin-aldosterone system, surgical remodeling, containment devices and new methods to restore synchronous contraction have been added to the armamentarium, in some instances, providing clear improvement to both symptoms and mortality. In more advanced stages of heart failure, left ventricular-assist devices provide marked unloading of the failing ventricle and such therapy has provided unique insights into the molecular and cellular mechanisms underlying reverse remodeling, given the immediate access to cardiac tissue. Genetic and cellular approaches, as well as new small molecule targets, may provide future avenues for reverse remodeling of the failing heart, improving symptoms and disease outcome.",
keywords = "BH4, Cardiac function, Cardiac resynchronization therapy, Cardiac support device, Dyssynchrony, Heart failure, Left ventricular-assist device, PDE5a, Reverse remodelling",
author = "James Mudd and Kass, {David A.}",
year = "2007",
month = "5",
doi = "10.1586/14779072.5.3.585",
language = "English (US)",
volume = "5",
pages = "585--598",
journal = "Expert Review of Cardiovascular Therapy",
issn = "1477-9072",
publisher = "Expert Reviews Ltd.",
number = "3",

}

TY - JOUR

T1 - Reversing chronic remodeling in heart failure

AU - Mudd, James

AU - Kass, David A.

PY - 2007/5

Y1 - 2007/5

N2 - Chronic heart failure is a debilitating condition with significant morbidity, mortality and an increasing economic burden. The past 20 years have witnessed great strides in both medical and device-based therapies for heart failure. Central to these developments has been the ability to favorably reverse the chronic processes by which the failing heart remodels. In addition to pharmacotherapies, such as β-blockade, and inhibition of the renin-angiotensin-aldosterone system, surgical remodeling, containment devices and new methods to restore synchronous contraction have been added to the armamentarium, in some instances, providing clear improvement to both symptoms and mortality. In more advanced stages of heart failure, left ventricular-assist devices provide marked unloading of the failing ventricle and such therapy has provided unique insights into the molecular and cellular mechanisms underlying reverse remodeling, given the immediate access to cardiac tissue. Genetic and cellular approaches, as well as new small molecule targets, may provide future avenues for reverse remodeling of the failing heart, improving symptoms and disease outcome.

AB - Chronic heart failure is a debilitating condition with significant morbidity, mortality and an increasing economic burden. The past 20 years have witnessed great strides in both medical and device-based therapies for heart failure. Central to these developments has been the ability to favorably reverse the chronic processes by which the failing heart remodels. In addition to pharmacotherapies, such as β-blockade, and inhibition of the renin-angiotensin-aldosterone system, surgical remodeling, containment devices and new methods to restore synchronous contraction have been added to the armamentarium, in some instances, providing clear improvement to both symptoms and mortality. In more advanced stages of heart failure, left ventricular-assist devices provide marked unloading of the failing ventricle and such therapy has provided unique insights into the molecular and cellular mechanisms underlying reverse remodeling, given the immediate access to cardiac tissue. Genetic and cellular approaches, as well as new small molecule targets, may provide future avenues for reverse remodeling of the failing heart, improving symptoms and disease outcome.

KW - BH4

KW - Cardiac function

KW - Cardiac resynchronization therapy

KW - Cardiac support device

KW - Dyssynchrony

KW - Heart failure

KW - Left ventricular-assist device

KW - PDE5a

KW - Reverse remodelling

UR - http://www.scopus.com/inward/record.url?scp=34249275677&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34249275677&partnerID=8YFLogxK

U2 - 10.1586/14779072.5.3.585

DO - 10.1586/14779072.5.3.585

M3 - Article

C2 - 17489680

AN - SCOPUS:34249275677

VL - 5

SP - 585

EP - 598

JO - Expert Review of Cardiovascular Therapy

JF - Expert Review of Cardiovascular Therapy

SN - 1477-9072

IS - 3

ER -